Oxford Genetics will begin scaling up its gene therapy manufacturing services after being awarded six licencing deals for the technologies. The company has already begun to develop a new generation of gene-editing technology that can be used in human clinical trials and is working with partners on developing an additional type of gene therapy. The remaining agreements are confidential deals secured with large pharmaceutical firms.
Oxford Genetics will begin scaling up its gene therapy manufacturing services after being awarded six licencing deals for the technologies. The agreements include a licence from Aldevron to bring Oxford's Lentiviral Plasmids therapy to market and a collaborative project with Sphere Fluidics to develop automated microfluidic systems for gene editing in mammalian cells. The remaining agreements are confidential deals secured with large pharmaceutical firms.